Australia's most trusted
source of pharma news
Tuesday, 01 July 2025
Posted 16 June 2025 AM
The TGA has approved Accelagen’s new multiple sclerosis treatment Briumvi, which was recently considered for reimbursement by the PBAC.
Administered via intravenous infusion, the anti-CD20 antibody is indicated for the treatment of adult patients with relapsing forms of multiple sclerosis with active disease defined by clinical or imaging features.
Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.